Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA4 | P48058 | 13/20 | 0.62 |
| ▸ | PSEN1 | P49768 | 2/20 | 0.48 |
| ▸ | PSEN2 | P49810 | 2/20 | 0.48 |
| ▸ | APH1B | Q8WW43 | 2/20 | 0.48 |
| ▸ | NCSTN | Q92542 | 2/20 | 0.48 |
| ▸ | APH1A | Q96BI3 | 2/20 | 0.48 |
| ▸ | PSENEN | Q9NZ42 | 2/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.46 |
| ▸ | KDM1A | O60341 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6573755 | 0.86 | GRIA4 (0.48) | GRIA4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6574456 | 0.86 | GRIA4 (0.47) | GRIA4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6575726 | 0.82 | GRIA4 (0.67) | GRIA4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL14511723 | 0.80 | GRIA4 (0.70) | GRIA4GRIA2KDM1A | |
| SCHEMBL6761964 | 0.80 | GRIA4 (0.43) | GRIA4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6573321 | 0.80 | GRIA4 (0.42) | GRIA4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6573336 | 0.79 | GRIA4 (0.41) | GRIA4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6573845 | 0.79 | GRIA4 (0.41) | GRIA4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6761010 | 0.78 | GRIA4 (0.41) | GRIA4PSEN1PSEN2APH1BNCSTN | |
| SCHEMBL6762192 | 0.78 | GRIA4 (0.40) | GRIA4PSEN1PSEN2APH1BNCSTN |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | DAVISON JOSHUA ZWICK (US) | 2004-07-29 | — | — | US | disclosed |
| EP-1409452-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2004-04-21 | — | — | EP | disclosed |
| WO-2002098846-A1 | SULFONAMIDE DERIVATIVES | ELI LILLY AND COMPANY (US) | 2002-12-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040147612-A1 | Sulfonamide derivatives | GRIN1, GRIN2A, GRIA1 | GRIA4 9/4885PSEN1 265/4885PSEN2 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.